Reports Q4 revenue $398M, consensus $397.95M. "We made key advances in strengthening our strategic path. We met our organic growth and exceeded our adjusted EPS guidance for the year. I am proud of our colleagues for being responsible stewards of our business in a challenging macro and supply environment. We remained focused on doing right by our customers and patients, while delivering on our financial commitments to our shareholders," said Jan De Witte, president and CEO. "Looking to 2023, our efforts have positioned us well to further accelerate our growth and investments in our strategic priorities as we move beyond the impacts of COVID-19 and supply challenges."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IART:
- Integra LifeSciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance
- Integra LifeSciences to Host Fourth Quarter 2022 Financial Results Conference Call on February 22, 2023
- Piper Sandler maintains cautious stance on Integra LifeSciences
- Integra LifeSciences sees Q4 EPS 92c-96c, consensus 89c
- Integra LifeSciences confirms Carrie Anderson to step down as CFO